Willingness to pay and conjoint analysis to determine women's preferences for ovarian stimulating hormones in the treatment of infertility in Spain
Rattachement africain : es, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Despite many advances in assisted reproductive techniques (ART), little is known about preferences for technological developments of women undergoing fertility treatments. The aims of this study were to investigate the preferences of infertile women undergoing ART for controlled ovarian stimulation (COS) treatments; to determine the utility values ascribed to different attributes of COS treatments; and to estimate women's willingness to pay (WTP) for COS. METHODS: A representative sample of ambulatory patients ready to receive, or receiving, COS therapies for infertility were recruited from seven specialized private centres in six autonomous communities in Spain. Descriptive, inferential and conjoint analyses (CA) were used to elicit preferences and WTP. Attributes and levels of COS treatments were identified by literature review and two focus groups with experts and patients. WTP valuations were derived by a combination of double-bounded (closed-ended) and open questions and contingent ranking methods. RESULTS: In total, 160 patients [mean (standard deviation; SD) age: 35.8 (4.2) years] were interviewed. Over half of the participants (55.0%) had a high level of education (university degree), most (78.8%) were married and half (50.0%) had an estimated net income of >€1502 per month and had paid a mean (SD) €1194.17 (€778.29) for their most recent hormonal treatment. The most frequent causes of infertility were related to sperm abnormalities (50.3%). In 30.6% of cases, there were two causes of infertility. The maximum WTP for COS treatment was €800 (median) per cycle; 35.5% were willing to pay an additional €101-€300 for a 1-2% effectiveness gain in the treatment. Utility values (CA) showed that effectiveness was the most valued attribute (39.82), followed by costs (18.74), safety (17.75) and information sharing with physicians (14.93). CONCLUSIONS: WTP for COS therapies exceeds current cost. Additional WTP exists for 1-2% effectiveness improvement. Effectiveness and costs were the most important determinants of preferences, followed by safety and information sharing with physicians.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Willingness to pay and conjoint analysis to determine women's preferences for ovarian stimulating hormones in the treatment of infertility in Spain
- Date Crossref
- 10/05/2011
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
IVI Madrid Clinic pays non établi dans la noticeÉtablissement de santé
-
Clínica IVI Alicante pays non établi dans la noticeÉtablissement de santé
-
Merck KGaA pays non établi dans la noticeEntreprise
-
Consorcio Hospitalario Provincial de Castellón pays non établi dans la noticeÉtablissement de santé
-
FIVAP pays non établi dans la noticeInstitution
-
CEFIVA pays non établi dans la noticeInstitution
-
IVI Castellón pays non établi dans la noticeInstitution
-
GINEMED pays non établi dans la noticeInstitution
-
IBILAB pays non établi dans la noticeStructure de recherche
-
Health Economics and Outcomes Research pays non établi dans la noticeInstitution
-
Outcomes’10 pays non établi dans la noticeInstitution
IVI Madrid Clinic, Clínica IVI Alicante et Merck KGaA, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.